Peptide YY reduces effects of sympathetic nerves and neuropeptide Y on cardiac vagal action.
In anesthetized dogs intravenous injection of neuropeptide Y (NPY) or stimulation of the cardiac sympathetic nerve is followed by a period of attenuation of vagal action at the heart lasting from many minutes to over an hour. Peptide YY (PYY), a related peptide (but one not reported to occur in the heart or its autonomic innervation), also inhibits cardiac vagal action but is more powerful and has a longer duration action. In 5 of 9 dogs, cardiac sympathetic nerve stimulation inhibited vagal action on the heart in control conditions, but relieved preexisting inhibition when repeated in the presence of PYY. In 3 dogs, exogenous NPY inhibited cardiac vagal action in control conditions, but failed to augment preexisting inhibition in the presence of PYY. An explanation offered for these results is that when PYY is occupying receptors on vagal nerve terminals, nerve-released NPY or exogenous NPY is either unable to produce an effect, because it cannot gain access to the receptors, or displaces PYY from at least some receptors and, being less powerful than PYY in its inhibitory action, lessens the preexisting vagal attenuation. The results reported are consistent with the proposal that the factor released from the sympathetic nerves following their stimulation and which is responsible for cardiac vagal inhibition is NPY.
Potter
E K
EK
Prince of Wales Medical Research Institute, Prince of Wales Hospital, Randwick, Sydney, Australia.
McCloskey
D I
DI
D000818:Animals; D004285:Dogs; D005768:Gastrointestinal Hormones / Q000494:pharmacology*; D006321:Heart / Q000294:innervation*; D009478:Neuropeptide Y / Q000494:pharmacology*; D019894:Peptide YY; D010455:Peptides / Q000494:pharmacology*; D013564:Sympathetic Nervous System / Q000187:drug effects / Q000502:physiology*; D014630:Vagus Nerve / Q000187:drug effects*
D005768:Gastrointestinal Hormones; D009478:Neuropeptide Y; D010455:Peptides; D019894:Peptide YY